Hemogenyx Pharmaceuticals PLC (HEMO) — Strategic Asset Allocation Index
Hemogenyx Pharmaceuticals PLC (HEMO) has a Strategic Asset Allocation Index of 95.8% as of June 2023. Strategic assets (PP&E of GBX3.48 Million plus long-term investments of GBX-) total GBX3.48 Million, measured against net assets of GBX3.63 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Hemogenyx Pharmaceuticals PLC Strategic Asset Allocation Index (2016–2021)
This chart shows how Hemogenyx Pharmaceuticals PLC's Strategic Asset Allocation Index has evolved across 5 annual periods from 2016 to 2021. As of June 2023, the index stands at 95.8%, representing strategic assets of GBX3.48 Million against net assets of GBX3.63 Million GBX. Explore Hemogenyx Pharmaceuticals PLC (HEMO) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Hemogenyx Pharmaceuticals PLC (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Hemogenyx Pharmaceuticals PLC from 2016 to 2021, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see HEMO market cap.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 9.8% | GBX797.13K | GBX797.13K | GBX- | GBX8.17 Million | ▼ -20.9 pp |
| 2020 | 30.7% | GBX268.74K | GBX268.74K | GBX- | GBX875.68K | ▲ +12.6 pp |
| 2018 | 18.1% | GBX173.94K | GBX173.94K | GBX- | GBX959.17K | ▲ +9.1 pp |
| 2017 | 9.0% | GBX191.58K | GBX191.58K | GBX- | GBX2.13 Million | ▼ -10.5 pp |
| 2016 | 19.5% | GBX175.80K | GBX175.80K | GBX- | GBX903.71K | — |